Borderline resectable pancreatic ductal adenocarcinoma: a narrative review.

Authors

Rupesh Thapa Chhetri, Krisha Maharjan

Published in

Annals of medicine and surgery (2012). Volume 88. Issue 10. Pages 6654-6661. Epub Sep 02, 2026.

Abstract

Borderline resectable (BR) pancreatic ductal adenocarcinoma (PDAC) is a well-recognized entity with specific characteristics. Previously considered inoperable, these tumors are now increasingly resectable due to advances in neoadjuvant chemotherapy. This review synthesizes current knowledge on diagnostic, therapeutic, and management approaches for pancreatic ductal adenocarcinoma, especially for BR disease. It covers the definition, criteria, and surgical management, along with various clinical challenges in the diagnosis of borderline disease. Neoadjuvant therapy is the treatment of choice before surgery, but there are still limited data on the selection of optimal therapy and on the early identification of non-responders. Multidetector computed tomography, along with CA19-9 and positron emission tomography, are being used to evaluate resectability after neoadjuvant therapy. Pancreatic resection for PDAC is one of the most complex procedures in abdominal surgery due to the technical and oncological challenges associated with its aggressive growth. Despite these options, management remains challenging.

PMID:
42866755
Bibliographic data and abstract were imported from PubMed on 14 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.